US FDA approves Bluebird Bio’s gene therapy for rare neurological disorder
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma
Cancer CART therapy: What are the benefits and stakes?
Hitachi Chemical Advanced Therapeutics Solutions, apceth Biopharma GmbH and bluebird bio to collaborate on strategic clinical and commercial manufacturing
Bluebird bio, Bristol-Myers’ multiple myeloma therapy shows promise in early study